Neurosense Therapeutics Ltd (NRSN) - Net Assets
Based on the latest financial reports, Neurosense Therapeutics Ltd (NRSN) has net assets worth $-1.56 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.03 Million) and total liabilities ($2.59 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore total assets of Neurosense Therapeutics Ltd for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-1.56 Million |
| % of Total Assets | -151.75% |
| Annual Growth Rate | N/A |
| 5-Year Change | -117.32% |
| 10-Year Change | N/A |
| Growth Volatility | 544.83 |
Neurosense Therapeutics Ltd - Net Assets Trend (2019–2025)
This chart illustrates how Neurosense Therapeutics Ltd's net assets have evolved over time, based on quarterly financial data. Check how tangible is Neurosense Therapeutics Ltd's equity to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Neurosense Therapeutics Ltd (2019–2025)
The table below shows the annual net assets of Neurosense Therapeutics Ltd from 2019 to 2025. For live valuation and market cap data, see NRSN market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-1.56 Million | -160.39% |
| 2024-12-31 | $2.58 Million | +246.84% |
| 2023-12-31 | $-1.76 Million | -131.30% |
| 2022-12-31 | $5.62 Million | -37.61% |
| 2021-12-31 | $9.01 Million | +1266.62% |
| 2020-12-31 | $659.00K | -28.21% |
| 2019-12-31 | $918.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Neurosense Therapeutics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4620800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $46.23 Million | % |
| Total Equity | $-1.56 Million | 100.00% |
Neurosense Therapeutics Ltd Competitors by Market Cap
The table below lists competitors of Neurosense Therapeutics Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Voyageur Pharmaceuticals Ltd
V:VM
|
$16.79 Million |
|
Initiator Pharma A/S
ST:INIT
|
$16.80 Million |
|
AlphaVest Acquisition Corp Ordinary Shares
NASDAQ:ATMV
|
$16.80 Million |
|
Hui Srl
VI:HUI
|
$16.80 Million |
|
Zhonglu Co Ltd B
SHG:900915
|
$16.78 Million |
|
Artego Tg. Jiu
RO:ARTE
|
$16.77 Million |
|
INCREDIBLE INDUSTRIES LIMITED
NSE:INCREDIBLE
|
$16.77 Million |
|
Millennium Group International Holdings Limited Ordinary Shares
NASDAQ:MGIH
|
$16.76 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Neurosense Therapeutics Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,583,000 to -1,560,000, a change of -4,143,000 (-160.4%).
- Net loss of 11,125,000 reduced equity.
- New share issuances of 4,531,000 increased equity.
- Other factors increased equity by 2,451,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-11.12 Million | -713.14% |
| Share Issuances | $4.53 Million | +290.45% |
| Other Changes | $2.45 Million | +157.12% |
| Total Change | $- | -160.39% |
Book Value vs Market Value Analysis
This analysis compares Neurosense Therapeutics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.17 | $0.47 | x |
| 2020-12-31 | $0.12 | $0.47 | x |
| 2021-12-31 | $0.83 | $0.47 | x |
| 2022-12-31 | $0.49 | $0.47 | x |
| 2023-12-31 | $-0.13 | $0.47 | x |
| 2024-12-31 | $0.14 | $0.47 | x |
| 2025-12-31 | $-0.06 | $0.47 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Neurosense Therapeutics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-174.65%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -133.66% | 0.00% | 0.00x | 1.04x | $-1.32 Million |
| 2020 | -429.14% | 0.00% | 0.00x | 1.18x | $-2.89 Million |
| 2021 | -44.87% | 0.00% | 0.00x | 1.27x | $-4.94 Million |
| 2022 | -219.61% | 0.00% | 0.00x | 1.37x | $-12.90 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.93 Million |
| 2024 | -395.28% | 0.00% | 0.00x | 1.77x | $-10.47 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.97 Million |
Industry Comparison
This section compares Neurosense Therapeutics Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $128,838,508
- Average return on equity (ROE) among peers: -63.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Neurosense Therapeutics Ltd (NRSN) | $-1.56 Million | -133.66% | N/A | $16.79 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $143.70 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $9.08 Million | -66.39% | 1.81x | $335.61 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $-18.49 Million | 0.00% | 0.00x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $-2.01 Million | 0.00% | 0.00x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $10.89 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-22.51 Million | 0.00% | 0.00x | $3.66 Billion |
About Neurosense Therapeutics Ltd
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for t… Read more